Business Wire

Connections, Local Flavors, and Luxurious Experiences Top the 2026 Bacardi Cocktail Trends Report

17.11.2025 13:00:00 CET | Business Wire | Press release

Share

This year’s findings highlight a move towards more meaningful occasions, micro-indulgence, and storytelling cocktail experiences

The five defining trends set to reshape cocktail culture and the spirits industry in 2026 are highlighted in the seventh annual Bacardi Cocktail Trends Report. The Report released by Bacardi Limited, the largest privately held international spirits company, in partnership with The Future Laboratory (TFL), draws on data from Bacardi-led and third-party research, consumer surveys, bartender interviews and TFL’s trend forecasting to uncover the forces shaping cocktail experiences, flavor innovation, and drinking culture in the year ahead. The Report also reveals the cocktails which are set to be the most popular in 2026 and trends for younger Legal Drinking Age (LDA) consumers.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117678098/en/

The 7th annual Bacardi Cocktail Trends Report unveils what and how people will be drinking in 2026.

“Gen Z isn’t drinking less, they’re simply drinking earlier, lighter, and with more intention,” says Sean Kerry, Vice President for Global On-Trade for Bacardi. “Around the world, we’re seeing a move towards more meaningful drinking moments whether that means in-person get-togethers with friends, discovering flavors rooted in local culture, or embracing new forms of creative expression through cocktails.”

"Consumers are moving from curating experiences to cultivating connections. The pendulum has swung from digital convenience to human creativity, and the drinks industry sits at the center of that shift,” says Martin Raymond, Co-Founder of The Future Laboratory. “In 2026, value will be defined not by scarcity or status, but by depth: the provenance of ingredients, the stories behind serves, and the ability to transform a moment into meaning.”

Here are the macro-trends defining the spirits industry in 2026:

1. AFTERNOON SOCIETY

Happy hour is having a cultural renaissance as earlier-day indulgence replaces late-night excess. The rise of "daycaps" (cocktails enjoyed in the late afternoon to close the workday) marks a shift toward micro-celebrations that fit modern routines. Across regions, people are heading out to drink, eat, and socialize earlier in the evenings. Notably, younger LDA consumers are leading the charge, with over half of those in France (51%) and more than one third in the U.S. (34%) reshaping routines around earlier evenings, according to the Bacardi Global Consumer Survey (GCS). Daytime drinking now revolves around Spritz culture, mood-based cocktails, and small serves that tap into the sweet treat economy. It’s not about escape; it’s about new rhythm and new routines of enjoyment that fit your energy and your calendar.

2. REWILDING CONNECTION

As social life recalibrates away from constant connectivity, drinkers are seeking intentional, offline experiences that prioritize presence over performance. With 84% of consumers saying technology has made social interactions feel less personal, bars and brands are designing shared, analog moments that feel human again—think screen-free gatherings, communal serves, analog entertainment, and rituals that spark real conversation. From martini flights to micro-format gatherings, Rewilding Connection reflects a consumer desire to slow down, tune back in, and rediscover the social magic of enjoying a cocktail together.

3. NEW LOCALOGY

As changing trade conditions and transparency reshape the industry, bars are evolving into laboratories of local flavor – harnessing micro-farms, regional ecologies, and scientific experimentation to pioneer a new future of mixology. This movement is not about replacing internationally celebrated spirits, but about elevating them through locally sourced ingredients, garnishes, and flavor accents that root each serve in its environment. Here, every sip is as much about terroir and technique as it is about transparency – catering to new consumer preferences to savor not only the flavor, but the place and process behind it. In fact, three-quarters (77%) check ingredient origin labels, seeking locally sourced ingredients.

4. THE LIQUID EXPERIENCE IP

No longer just vessels for a taste experience, cocktails and drinks brands are transforming into full spectrum lifestyle experiences that blend fashion, music, design, travel and sport into cohesive cultural identities. Gen Z and millennials choose brands that reflect their identity, and 70% of people who say emotional engagement drives loyalty. Bars and brands are responding with immersive cocktail worlds, drink characters, playlist pairings, traveling pop-up menus, and branded sensory elements like scent, sound, and storytelling. In 2026, a cocktail isn’t just ordered; it’s experienced, collected, and followed like a creator brand.

5. MORE IS MORE MIXOLOGY

After years of “quiet luxury” minimalism, maximalism is back behind the bar with showstopping cocktails full of glamor and theatrics. Over three quarters of the Bacardi GCS participants (76%) value heightened, memorable experiences as bars embrace edible pearls, metallic garnishes, evolving flavor layers, fire presentations, and high-drama glassware. Loud luxury venues—from Dubai to Las Vegas—prove that joyfully excessive design and unapologetic opulence are in. In a world still healing from burnout, people don’t just want a drink, they want a moment.

Globally, the top 10 cocktails in 2026 will be:

  1. Margarita
  2. Mojito
  3. Piña Colada
  4. Rum and Coke®
  5. Whisky and Coke®
  6. Spritz
  7. Vodka Lemonade
  8. Vodka Soda
  9. Gin & Tonic
  10. Dry Martini Cocktail

Download the complete 2026 Bacardi Cocktail Trends Report and Infographic.

About Bacardi Limited

Bacardi Limited, the world’s largest privately held international spirits company, produces, markets, and distributes spirits and wines. The Bacardi Limited portfolio comprises more than 200 brands and labels, including BACARDÍ® rum, PATRÓN® tequila, GREY GOOSE® vodka, DEWAR’S® Blended Scotch whisky, BOMBAY SAPPHIRE® gin, MARTINI® vermouth and sparkling wines, CAZADORES® 100% blue agave tequila, and other leading and emerging brands including D’USSÉ® Cognac, ANGEL’S ENVY® American straight whiskey, and ST-GERMAIN® elderflower liqueur. Founded more than 163 years ago in Santiago de Cuba, family-owned Bacardi Limited currently employs approximately 8,000, operates production facilities in 10 countries and territories, and sells its brands in more than 160 markets. Bacardi Limited refers to the Bacardi group of companies, including Bacardi International Limited. Visit http://www.bacardilimited.com or follow us on LinkedIn and Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251117678098/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye